United Therapeutics Corp. (NASDAQ:UTHR) COO Roger Jeffs sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $96.61, for a total transaction of $966,100.00. Following the completion of the transaction, the chief operating officer now directly owns 897 shares in the company, valued at approximately $86,659. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
A number of analysts have recently weighed in on UTHR shares. Analysts at Zacks upgraded shares of United Therapeutics Corp. from a “neutral” rating to an “outperform” rating in a research note to investors on Friday, January 24th. They now have a $135.00 price target on the stock. Separately, analysts at Argus raised their price target on shares of United Therapeutics Corp. from $120.00 to $130.00 in a research note to investors on Tuesday, December 31st. They now have a “buy” rating on the stock. They noted that the move was a valuation call. Finally, analysts at Jefferies Group raised their price target on shares of United Therapeutics Corp. from $76.00 to $91.00 in a research note to investors on Tuesday, December 24th. They now have a “hold” rating on the stock. Eight investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $91.07.
United Therapeutics Corp. (NASDAQ:UTHR) opened at 97.66 on Monday. United Therapeutics Corp. has a one year low of $52.98 and a one year high of $116.65. The stock’s 50-day moving average is $107.6 and its 200-day moving average is $87.85. The company has a market cap of $4.905 billion and a P/E ratio of 17.66.
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.